Skip to Content

Aptivus Approval History

  • FDA approved: Yes (First approved June 22nd, 2005)
  • Brand name: Aptivus
  • Generic name: tipranavir
  • Dosage form: Capsules
  • Company: Boehringer Ingelheim
  • Treatment for: HIV Infection

Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.

Development History and FDA Approval Process for Aptivus

Jun 24, 2008Approval New Aptivus (tipranavir) Oral Solution Approved forTreatment-Experienced Pediatric and Adolescent HIV Patients
Oct  5, 2007Approval Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Jun 22, 2005Approval FDA Approves Aptivus for HIV Infection
May 19, 2005FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir
Oct 25, 2004Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.